Assenagon Asset Management S.A. Sells 70,521 Shares of Merit Medical Systems, Inc. $MMSI

Key Points

• Assenagon Asset Management reduced its Merit Medical Systems stake by 34.2% in the second quarter, selling 70,521 shares and retaining 135,381 shares valued at approximately $9.4 million. Institutional investors collectively own 99.66% of the company.
• Merit Medical reported quarterly EPS of $1.19, beating expectations of $0.96, while revenue rose 9.5% year over year to $418.84 million. The company issued fiscal 2026 EPS guidance of $4.25–$4.35.
• Analysts remain broadly positive, with eight Buy ratings and three Holds, an overall “Moderate Buy” consensus, and an average price target of $100.30 versus the stock’s reported $91.11 price.

Assenagon Asset Management S.A. cut its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 34.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 135,381 shares of the medical instruments supplier's stock after selling 70,521 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.23% of Merit Medical Systems worth $9,387,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MMSI. AQR Capital Management LLC boosted its position in Merit Medical Systems by 7.3% in the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier's stock worth $1,730,000 after purchasing an additional 1,114 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier's stock valued at $76,039,000 after purchasing an additional 103,878 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Merit Medical Systems by 745.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier's stock valued at $86,000 after purchasing an additional 813 shares during the last quarter. First Trust Advisors LP increased its position in shares of Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier's stock valued at $5,535,000 after purchasing an additional 11,770 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier's stock worth $282,000 after purchasing an additional 251 shares during the period. 99.66% of the stock is owned by institutional investors.

Merit Medical Systems Stock Performance

NASDAQ MMSI opened at $91.11 on Wednesday. The firm has a market cap of $5.44 billion, a P/E ratio of 37.65, a price-to-earnings-growth ratio of 2.26 and a beta of 0.49. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The company's 50 day moving average is $73.37 and its 200-day moving average is $72.01. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $94.75.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The company had revenue of $418.84 million during the quarter, compared to the consensus estimate of $405.25 million. During the same period last year, the firm earned $1.01 EPS. Merit Medical Systems's revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Sell-side analysts predict that Merit Medical Systems, Inc. will post 3.81 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on MMSI shares. BTIG Research reissued a "buy" rating and issued a $105.00 price target on shares of Merit Medical Systems in a report on Tuesday. Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a report on Friday, July 31st. Robert W. Baird set a $98.00 price objective on shares of Merit Medical Systems in a research report on Friday, July 31st. Canaccord Genuity Group boosted their target price on shares of Merit Medical Systems from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their target price on shares of Merit Medical Systems from $77.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $100.30.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source